di·dan·o·sine (d -d n  -s n, -s n )n. See ddI. |
didanosine.
didanosine
sin´), n brand name: Videx;
drug class: synthetic antiviral;
action: converted by cellular enzymes that act as antimetabolites to inhibit HIV replication;
uses: advanced HIV infections in adults and children who have been unable to use zidovudine or who have not responded to treatment with zidovudine.
didanosine (ddI, 2,3-dideoxyinosine)
Videx, Videx EC
Pharmacologic class: Nucleoside reverse transcriptase inhibitor
Therapeutic class: Antiretroviral, antiviral
Pregnancy risk category B
FDA Boxed Warning
• Pancreatitis has occurred when drug was used alone or in combination regimens in treatment-naive or treatment-experienced patients. Suspend therapy in patients with suspected pancreatitis; discontinue in patients with confirmed pancreatitis.
• Drug may cause lactic acidosis and severe hepatomegaly with steatosis when used alone or in combination with other antiretrovirals. Fatal lactic acidosis has occurred in pregnant women receiving didanosine-stavudine combination with other antiretrovirals. In pregnant patients, use this combination with caution and only if benefit clearly outweighs risk.
Action
Inhibits replication of human immunodeficiency virus (HIV) by disrupting synthesis of DNA polymerase, an enzyme crucial to DNA and RNA formation
Availability
Capsules (delayed-release): 125 mg, 200 mg, 250 mg, 400 mg
Powder for oral solution (buffered): 100 mg/packet, 167 mg/packet, 250 mg/packet
Powder for oral solution (pediatric): 2 g in 4-oz glass bottle, 4 g in 8-oz glass bottle
Tablets (buffered, chewable): 25 mg, 50 mg, 100 mg, 150 mg, 200 mg
⊘Indications and dosages
➣ HIV infection
Adults weighing 60 kg (132 lb) or more: 200 mg (tablets) P.O. q 12 hours, or 400 mg (capsules) P.O. once daily, or 250 mg (buffered powder) P.O. q 12 hours
Adults weighing less than 60 kg (132 lb): 125 mg (tablets) P.O. q 12 hours, or 250 mg (capsules) P.O. once daily, or 167 mg (buffered powder) P.O. q 12 hours
Children: 120 mg/m2 (tablets or powder for oral solution, pediatric) P.O. q 12 hours
Dosage adjustment
• Renal impairment
Contraindications
• Hypersensitivity to drug
Precautions
Use cautiously in:
• renal or hepatic impairment, peripheral neuropathy, phenylketonuria, hyperuricemia
• elderly patients
• pregnant or breastfeeding patients
• children.
Administration
• Know that drug is usually given in conjunction with other antiretrovirals.
• Give on empty stomach 30 minutes before or 2 hours after a meal.
• Don't administer with fruit juice.
• Know that pharmacist must prepare pediatric powder for oral solution by diluting with water and antacid to a concentration of 10 mg/ml.
• Be aware that delayed-release capsules aren't intended for use in children.
| Route | Onset | Peak | Duration |
| P.O. | Unknown | 0.5-1 hr | Unknown |
Adverse reactions
CNS: dizziness, anxiety, abnormal thinking, hypoesthesia, agitation, confusion, hypertonia, asthenia, peripheral neuropathy, seizures , coma
CV: peripheral coldness, palpitations, hypotension, bradycardia, weak pulse, pseudoaneurysm, incomplete atrioventricular (AV) block, complete AV block, nodal arrhythmias, ventricular tachycardia , thrombophlebitis, embolism
EENT: diplopia, abnormal vision, ocular hypotony, iritis, retinal detachment
GI: nausea, vomiting, diarrhea, abdominal enlargement, dyspepsia, ileus, GI reflux, hematemesis, dysphagia, dry mouth, pancreatitis
GU: urinary retention, frequency, or incontinence; dysuria; cystalgia; prostatitis; renal dysfunction; nephrotoxicity
Hematologic: anemia, leukocytosis, thrombocytopenia, bleeding, neutropenia
Hepatic: hepatomegaly with steatosis
Metabolic: diabetes mellitus, hyperkalemia, lactic acidosis
Musculoskeletal: muscle contractions
Respiratory: pneumonia, crackles, rhonchi, bronchitis, pleurisy, dyspnea, wheezing, pleural effusion , pulmonary edema , pulmonary embolism , bronchospasm
Skin: diaphoresis, pallor, rash, urticaria, pruritus, bullous eruption, petechiae, cellulitis, abscess
Other: edema, development of human antichimeric antibodies
Interactions
Drug-drug. Allopurinol, ganciclovir (oral): increased didanosine blood level
Amprenavir, delavirdine, indinavir, ritonavir, saquinavir: altered didanosine pharmacokinetics
Antacids, other drugs that increase gastric pH: increased risk of didanosine toxicity
Co-trimoxazole, pentamidine: increased risk of pancreatic toxicity
Dapsone, fluoroquinolones, ketoconazole: decreased blood levels of these drugs
Itraconazole: decreased itraconazole blood level
Methadone: 50% decrease in didanosine blood level
Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, uric acid: increased levels
Granulocytes, hemoglobin, platelets, white blood cells: decreased values
Drug-food. Any food: decreased rate and extent of drug absorption
Patient monitoring
☞ Monitor for signs and symptoms of pancreatitis. Report these to prescriber immediately.
☞ Assess carefully for signs and symptoms of lactic acidosis, such as dizziness, light-headedness, and bradycardia.
• Monitor for signs and symptoms of peripheral neuropathy.
• In patients with renal impairment, watch for drug toxicity and hypermagnesemia (suggested by muscle weakness and confusion).
Patient teaching
• Tell patient to take drug on empty stomach and to chew tablets without crushing or breaking.
• Advise patient using buffered powder to mix it with water, not juice, and to let powder dissolve for several minutes before taking.
☞ Instruct patient to immediately report abdominal pain, nausea, or vomiting.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and foods mentioned above.
didanosine
How to thank TFD for its existence? Tell a friend about us, add a link to this page, add the site to iGoogle, or visit webmaster's page for free fun content.
| ?Page tools | ||
|---|---|---|
|